Spotlight Therapeutics, a Bay Area biotech company that raised $66 million from investors, including GV, has shut down.

San Francisco, California-- (Newsfile Corp. - February 20, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase ...

Bollywood actress Tabu reacted to the buzz of the possible reunion of the lead cast of 'Hera Pheri' for its third instalment which is being directed by Priyadarshan. On the occasion of ...

Jefferies analyst James Vane maintained a Buy rating on Sartorius Stedim Biotech (0RG8 – Research Report) today and set a price target of €269.00. The company’s shares closed yesterday at ...

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Metsera is a clinical-stage biotechnology company developing injectable and oral treatments for obesity and related conditions, the filing shows. The company’s investors include affiliates of ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives.

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

Only one traditional preclinical biotech—Metagenomi—went public last year, compared to around a quarter of the biotechs that IPOed in 2020 and 2021, according to Surti. About two-thirds of the ...

Canada has long punched above its weight in life sciences and biotechnology, with many of the fundamental discoveries that underpin today’s important blockbuster drugs and therapeutic approaches ...

EU targets AI, biotech, green tech, advance materials sectors Draghi report said EU is falling behind US and China France, Trump push EU to cut business red tape EU plans include 25% reduction of ...